Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance
David P. Hill, Akeena Harper, Joan Malcolm, et al.
BMC Cancer (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 105

Showing 1-25 of 105 citing articles:

Curcumin as an Enhancer of Therapeutic Efficiency of Chemotherapy Drugs in Breast Cancer
Reyhaneh Farghadani, Rakesh Naidu
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 4, pp. 2144-2144
Open Access | Times Cited: 81
HSPB1 facilitates chemoresistance through inhibiting ferroptotic cancer cell death and regulating NF-κB signaling pathway in breast cancer
Yiran Liang, Yajie Wang, Yan Zhang, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 7
Open Access | Times Cited: 46
HDAC2‐Mediated METTL3 Delactylation Promotes DNA Damage Repair and Chemotherapy Resistance in Triple‐Negative Breast Cancer
Xiaoniu He, Yuanpei Li, Jian Li, et al.
Advanced Science (2025)
Open Access | Times Cited: 2
Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment
Robert Kiss, Fen Xia, Scarlett Acklin
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 15, pp. 8199-8199
Open Access | Times Cited: 93
Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors
Lisa Agnello, Silvia Tortorella, Annachiara d’Argenio, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 71
Heteroleptic Pd(II) and Pt(II) Complexes with Redox-Active Ligands: Synthesis, Structure, and Multimodal Anticancer Mechanism
N. F. Romashev, Pavel A. Abramov⧫, I. V. Bakaev, et al.
Inorganic Chemistry (2022) Vol. 61, Iss. 4, pp. 2105-2118
Closed Access | Times Cited: 45
Co-Delivery of Hesperetin and Cisplatin via Hyaluronic Acid-Modified Liposome for Targeted Inhibition of Aggression and Metastasis of Triple-Negative Breast Cancer
Xiangpeng Wang, Yurong Song, Liuchunyang Yu, et al.
ACS Applied Materials & Interfaces (2023) Vol. 15, Iss. 29, pp. 34360-34377
Closed Access | Times Cited: 27
Enhancement of targeted therapy in combination with metformin on human breast cancer cell lines
Ghazal Mahmoudi, Yahya Ehteshaminia, Parviz Kokhaei, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 10
Classifications of triple-negative breast cancer: insights and current therapeutic approaches
Ziqi Chen, Yumeng Liu, Mingzhi Lyu, et al.
Cell & Bioscience (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Folic acid conjugated chitosan encapsulated palladium nanoclusters for NIR triggered photothermal breast cancer treatment
Anbazhagan Sathiyaseelan, Kandasamy Saravanakumar, Panchanathan Manivasagan, et al.
Carbohydrate Polymers (2021) Vol. 280, pp. 119021-119021
Closed Access | Times Cited: 54
A conjugated 2D covalent organic framework as a drug delivery vehicle towards triple negative breast cancer malignancy
Sabuj Kanti Das, Sraddhya Roy, Ananya Das, et al.
Nanoscale Advances (2022) Vol. 4, Iss. 10, pp. 2313-2320
Open Access | Times Cited: 29
The Importance of Being Casiopeina as Polypharmacologycal Profile (Mixed Chelate–Copper (II) Complexes and Their In Vitro and In Vivo Activities)
Zenayda Aguilar-Jiménez, Adrián Espinoza-Guillén, Karen Reséndiz-Acevedo, et al.
Inorganics (2023) Vol. 11, Iss. 10, pp. 394-394
Open Access | Times Cited: 21
Focus on the molecular mechanisms of cisplatin resistance based on multi-omics approaches
Ping Yue, Bing-Jie Han, Yi Zhao
Molecular Omics (2023) Vol. 19, Iss. 4, pp. 297-307
Closed Access | Times Cited: 20
Implications of nanotherapeutic advancements to leverage multi-drug resistant breast cancer: The state-of-the-art review
Adhithya Aravindan, Ashutosh Gupta, Sudheer Moorkoth, et al.
Journal of Drug Delivery Science and Technology (2024) Vol. 100, pp. 106007-106007
Open Access | Times Cited: 8
Computer-Aided Ligand Discovery for Estrogen Receptor Alpha
Divya Bafna, Fuqiang Ban, Paul S. Rennie, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 12, pp. 4193-4193
Open Access | Times Cited: 48
Cancer cell-selective modulation of mitochondrial respiration and metabolism by potent organogold(iii) dithiocarbamates
R. Tyler Mertens, Sean Parkin, Samuel G. Awuah
Chemical Science (2020) Vol. 11, Iss. 38, pp. 10465-10482
Open Access | Times Cited: 43
Senescence-Induced Chemoresistance in Triple Negative Breast Cancer and Evolution-Based Treatment Strategies
Anindita Chakrabarty, Shayantani Chakraborty, Ranjini Bhattacharya, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 40
Decomposable black phosphorus nano-assembly for controlled delivery of cisplatin and inhibition of breast cancer metastasis
Yuanyuan Li, Jianming Xiong, Wenjing Guo, et al.
Journal of Controlled Release (2021) Vol. 335, pp. 59-74
Closed Access | Times Cited: 37
Cisplatin uptake and release assessment from hydrogel synthesized in acidic and neutral medium: An experimental and molecular dynamics simulation study
Iman Salahshoori, Zohreh Ramezani, Ilaria Cacciotti, et al.
Journal of Molecular Liquids (2021) Vol. 344, pp. 117890-117890
Closed Access | Times Cited: 33
Inhibition of Bone Marrow-Mesenchymal Stem Cell-Induced Carbonic Anhydrase IX Potentiates Chemotherapy Efficacy in Triple-Negative Breast Cancer Cells
Annachiara Sarnella, Ylenia Ferrara, Sandra Albanese, et al.
Cells (2023) Vol. 12, Iss. 2, pp. 298-298
Open Access | Times Cited: 14
BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy
Sushmitha Sriramulu, Shivani Thoidingjam, Farzan Siddiqui, et al.
Biomolecules (2024) Vol. 14, Iss. 6, pp. 625-625
Open Access | Times Cited: 5
The Premature Senescence in Breast Cancer Treatment Strategy
Małgorzata Milczarek
Cancers (2020) Vol. 12, Iss. 7, pp. 1815-1815
Open Access | Times Cited: 37
STAMBPL1 promotes breast cancer cell resistance to cisplatin partially by stabilizing MKP-1 expression
Rong Liu, Guangxi Yang, Min Bao, et al.
Oncogene (2022) Vol. 41, Iss. 16, pp. 2265-2274
Closed Access | Times Cited: 20
Hitting Multiple Cellular Targets in Triple-Negative Breast Cancer Using Dual-Action Cisplatin(IV) Prodrugs for Safer Synergistic Chemotherapy
Tushar Date, Kaushik Kuche, Dasharath Chaudhari, et al.
ACS Biomaterials Science & Engineering (2022) Vol. 8, Iss. 6, pp. 2349-2362
Closed Access | Times Cited: 20
SOCS1 acts as a ferroptosis driver to inhibit the progression and chemotherapy resistance of triple-negative breast cancer
Yiding Wang, Xiaoling Pang, Yuexin Liu, et al.
Carcinogenesis (2023) Vol. 44, Iss. 8-9, pp. 708-715
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top